K Fiaccadori

Humanitas University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Pietro Invernizzi

Azienda Ospedaliera San Gerardo

Elisa Forti

University of Modena and Reggio Emilia

Fabio Marra

University of Florence

Nadia Navari

University of Florence

Vincenzo Mazzaferro

Fondazione IRCCS Istituto Nazionale dei Tumori

Shannon Glaser

Texas A&M University

Alessio Gerussi

University of Milano-Bicocca

Giovanni Abbadessa

Sanofi (United States)

Chiara Raggi

University of Florence

Margherita Correnti

University of Milan

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

Humanitas University

University of Milan

University of Florence

Fondazione Humanitas per la Ricerca

Fondazione IRCCS Istituto Nazionale dei Tumori

Central Texas Veterans Health Care System

Azienda Ospedaliera San Gerardo

University of Milano-Bicocca

Arqule (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Zenodo (CERN European Organization for Nuclear Research) (2020)

Chiara Raggi K Fiaccadori Mirella Pastore Margherita Correnti Benedetta Piombanti

Fibroblast growth factor receptor 2 (FGFR2) might have an important role in the pathogenesis and biology of cholangiocarcinoma (CCA). We examined FGFR expression in CCA tumor specimens obtained from patients and CCA cell lines, and then determined the effects of the novel FGFR inhibitor, derazantinib (DZB; formally, ARQ 087), which is currently in clinical phase 2 trials for intrahepatic CCA. DZB inhibited the growth of CCA cell lines in a dose-dependent manner, and extracellular signal-regulated kinase 1/2 and AKT. It also activated apoptotic and cell growth arrest signaling. DZB reduced the in vitro invasiveness and the expression of key epithelial-mesenchymal transition genes. The in vitro data correlated with the expression of FGFRs in human CCA specimens by immunohistochemistry (FGFR1, 30% positive; and FGFR2, 65% positive) and the CCA cell lines assayed by Western blot analysis. These correlated in vitro studies suggest that FGFR may play an important role in the pathogenesis and biology of CCA. Our findings support the notion that FGFR inhibitors, like DZB, should be further evaluated at the clinical stage as targeted therapy for CCA treatment.

Intrahepatic Cholangiocarcinoma

10.5281/zenodo.3713331

Cite

Citations (0)

Zenodo (CERN European Organization for Nuclear Research) (2020)

Chiara Raggi K Fiaccadori Mirella Pastore Margherita Correnti Benedetta Piombanti

Intrahepatic Cholangiocarcinoma

10.5281/zenodo.3713332

Cite

Citations (0)

Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma

American Journal Of Pathology (2019)

Chiara Raggi K Fiaccadori Mirella Pastore Margherita Correnti Benedetta Piombanti

10.1016/j.ajpath.2019.06.007

Cite

Citations (18)